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Abstract
Background: The immune system has been implicated in neurodegeneration during development and disease. In
various studies, the absence of complement (that is, C1q deficiency) impeded the elimination of apoptotic neurons,
allowing survival. In the genetic lysosomal storage disease Niemann-Pick C (NPC), caused by loss of NPC1 function,
the expression of complement system components, C1q especially, is elevated in degenerating brain regions of
Npc1-/- mice. Here we test whether complement is mediating neurodegeneration in NPC disease.
Findings: In normal mature mice, C1q mRNA was found in neurons, particularly cerebellar Purkinje neurons (PNs).
In Npc1-/- mice, C1q mRNA was additionally found in activated microglia, which accumulate during disease
progression and PN loss. Interestingly, C1q was not enriched on or near degenerating neurons. Instead, C1q was
concentrated in other brain regions, where it partially co-localized with a potential C1q inhibitor, chondroitin sulfate
proteoglycan (CSPG). Genetic deletion of C1q, or of the downstream complement pathway component C3, did not
significantly alter patterned neuron loss or disease progression. Deletion of other immune response factors, a
Toll-like receptor, a matrix metalloprotease, or the apoptosis facilitator BIM, also failed to alter neuron loss.
Conclusion: We conclude that complement is not involved in the death and clearance of neurons in NPC disease.
This study supports a view of neuroinflammation as a secondary response with non-causal relationship to neuron
injury in the disease. This disease model may prove useful for understanding the conditions in which complement
and immunity do contribute to neurodegeneration in other disorders.




Elevated immune and inflammatory factors are suspect in
causing or promoting neurodegeneration in several neuro-
logical disorders. For the neurodegenerative lysosomal stor-
age disease Niemann-Pick C (NPC), multiple independent
gene profile studies analyzingNpc1-/-mouse tissues and pa-
tient blood samples have identified immune response and
inflammation pathway genes as the largest group whose ex-
pression is modified during disease progression [1]. Al-
though these genes can be used as indicators of disease
severity, the relevance of these inflammatory mediators to
the pathology remains unclear. Previously, we observed
that deletion of the inflammatory chemokine Ccl3 gene
did not have the beneficial effect on neurodegeneration
in NPC-diseased mice that was evident for another
lysosomal storage disorder, Sandhoff disease [2]. In
addition to chemokines, complement components, Toll-
like receptors, proteases, and apoptotic facilitators are
also found to be elevated in the brains of Npc1-/- mice.
Components in these pathways could play critical roles
in the disease progression. Here, we focus primarily on
defining the role of the innate immune complement
component C1q in NPC disease, since in other neuro-
degenerative scenarios C1q has been proposed to medi-
ate synapse removal and mark apoptotic neurons for
lysis and clearance [3-5].
Expression and localization of C1q in mice with NPC
disease
Using microarrays to analyze cerebellar mRNAs, inde-
pendent studies using the Npc1-/- NPC mouse model
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have found increased levels of complement genes, sug-
gesting that complement may play an important role in
the disease. The complement pathway involves serial
processing of several protein complexes [4]. The classical
complement cascade begins with C1q (C1qA, C1qB, and
C1qC complex). Elevated levels of C1qa, b, and c mRNA
have been detected in the cerebellum of Npc1-/- mice as
early as postnatal day 21 (P21), an age well before onset
of severe neurodegeneration [6,7] (Figure 1A). At around
P50, an age just prior to major decline in health, C1qa,
b, and c mRNA levels are markedly higher [2,7]. In
addition to the cerebellum, increased C1qa expression
Figure 1 C1q and complement component expression is increasingly elevated with age in NPC disease. (A) Compilation of analyses from
three independent cerebellar array datasets accessible through the National Center for Biotechnology Information (NCBI) Gene Expression
Omnibus (GEO) database: a, GSE36119; b, GSE5944; and c, GSE20450. The differential gene expression of components of the complement cascade
for Npc1-/- mice compared to wild-type, Npc1+/- or Npc1+/+, mice are shown at two ages. (B) An outline of the initial components of the
complement cascade (genes are in bold) showing factors in the pathway that have been identified as elevated in at least one array dataset. (C)
Representative in situ signal of C1qa mRNA probe hybridized to thalamic region of P60 wild-type, Npc1-/-, and C1qa-/-; Npc1-/- mice. Scale bars are
100μm.
Figure 2 C1qa expression is induced in microglia in the brains of NPC mice. (A) In wild-type mice, C1qa mRNA (left panel) and C1q protein
(right panel) localize to cerebellar PNs (yellow arrows; anti-D28K green). A rendering of stacked confocal images (right panel) shows speckles of
C1q (white arrow) internal to and proximal to the neuron. (B) In Npc1-/- mice, C1qa mRNA (left panel) and C1q protein (right panel) do not
localize entirely to PNs. (C) Overlay (right panel) of C1qa mRNA (left panel, magenta) with anti-D28K (middle panel, green). (D, top panel)
NBT/BCIP reaction from C1qa RNA in situ hybridization (dark purple) co-localizes with DAB anti-CD68 immunohistochemistry (brown) in Npc1-/-
mice. (D, bottom panel) In C1qa-/-; Npc1-/- mice, only the DAB staining can be seen. Scale bars are 10μm.
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was found in the thalamus (Figure 1C), another brain re-
gion that is highly vulnerable in the disease. Down-
stream gene components of the complement cascade
identified in cerebellar arrays include the anaphylatoxin
and opsonin precursor C3 and the anaphylatoxin recep-
tor C3aR. The mRNA of C3, which plays a central role
in complement activation (Figure 1B), is not as robustly
detected as C3aR (Figure 1A). The mRNAs of C1r and
C1s, components needed to initiate the classical comple-
ment cascade, are also not consistently elevated between
studies. However, even without efficient activation of the
complement cascade, C1q alone may act as a recogni-
tion molecule that tags apoptotic cells to facilitate their
clearance by phagocytes [5].
We next determined if C1q, a secreted molecule, loca-
lizes around degenerating neurons in the NPC mouse
model. In other neurodegenerative disease models, such
as amyotrophic lateral sclerosis [8] and glaucoma [3], C1q
is produced in and localizes around injured neurons. In
normal mice, we detected C1qa mRNA in cerebellar Pur-
kinje neurons (PNs) (Figure 2A). Antibody staining
showed that C1q co-localized with PN soma, marked by
Calbindin-D28K immunofluorescence. In Npc1-/- mice,
more abundant C1qa was detected in the cerebellum,
but the additional mRNA was not produced by the
degenerating PNs (Figure 2B, 2C). Instead, the major-
ity of the C1qa mRNA co-localized with CD68, a mar-
ker for activated microglia, which was detected using
3,30-diaminobenzidine tetrahydrochloride (DAB) immu-
nohistochemistry (Figure 2D). Strikingly, C1q protein
was not enriched in areas of neuron loss or high micro-
glia activity such as the cerebellar cortex, but was in-
stead concentrated in specific brain regions, for
example, the deep cerebellar nuclei (DCN) of the cere-
bellum (Figure 3A-D) and the CA2 region of the hippo-
campus (Figure 3E-G). Although many efferent axons of
degenerating neurons contact the DCN and CA2, DCN
and CA2 neurons are not extraordinarily vulnerable to
NPC-triggered degeneration [9]. Thus, in contrast to
other neurodegenerative conditions [3,8,10], C1q does
not preferentially mark degenerating neurons in NPC
disease.
It is possible that the extracellular matrix may pre-
cipitate C1q and arrest its activity during NPC
Figure 3 C1q does not preferentially accumulate in brain regions with degenerating neurons in NPC mice. (A) A simplified diagram of a
cerebellar lobule marks the location of activated microglia (MG), degenerating Purkinje neurons (PN), and their efferent axons (EA) that contact
the deep cerbellar nuclei (DCN) at the center of the cerebellum. (B, top panel) In the cerebellar cortex from an Npc1-/- mouse, abundant microglia
(anti-CD68, red) and few remaining PNs (Nissl stain, green; arrows) can be seen. (B, bottom panel) Microglia are also present throughout the
cerebellum, though visibly less swollen, near remaining DCN neuron bodies (Nissl stain, yellow; arrow). (C) C1qa mRNA can be detected
throughout the cerebellum. (D) Nevertheless, C1q protein (red) is found concentrated at the DCN in Npc1-/- mice. Hoechst nuclear stain (blue)
demarcates the cerebellar lobes. (E) Similarly, C1qa mRNA (dark purple) can be detected throughout the hippocampus, in microglia and neurons
in Npc1-/- mice. (F, top panel) Microglia (anti-CD68, red) evenly decorate the CA3, CA2, and CA1 neuron fields (anti-D28K, cyan), (F, bottom panel)
however C1q protein (red) concentrates at the CA2 region (bright cyan) opposite the stratum radiatum (sr) side of the CA3/CA2 field. (G) Analysis
of the C1q immunofluorescence intensity shows a peak difference between CA1 and CA2. Graph depicts the mean log fold change and 95%
confidence limit of fluorescent intensity between Npc1-/- and C1qa-/-; Npc1-/- mice compared to Npc1+/- and C1qa-/-; Npc1-/- mice. The average log
fold change of C1q immunofluorescence in C1qa-/-; Npc1-/- hippocampal neuron regions over tissue autofluorescence is 0.15 with a standard
deviation of 0.15. All images are representative of data observed in at least six mice at various ages >P50. Scale bars are 100μm.
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disease progression. DCN and CA2 neurons possess an
extensive perineuronal extracellular matrix (ECM) com-
position [11,12]. In the DCN and CA2, C1q partially
co-localized with the ECM component chondroitin sul-
fate proteoglycan (CSPG) (Figure 4A, 4B). Secreted
CSPGs are known to strongly bind C1q functional
domains, which may prevent C1q binding to the cell
surface, inhibit C1q complex formation with C1r and
C1s, and/or interfere with C1q binding to its receptor
on phagocytes [13]. Thus, C1q found around DCN and
CA2 neurons may be sequestered there and inactivated
by perineuronal CSPG. How C1q localizes to specific
brain regions, whether these regions are mainly efferent
axonal connections of degenerating neurons, and
whether C1q serves a function at these sites remains to
be investigated.
NPC-induced patterned neurodegeneration continues
despite genetic inactivation of complement
A common observation in genetic neurodegenerative
disorders is selective neuron vulnerability to ubiquitous
toxic factors [14]. In NPC disease, selective vulnerability
is easily traceable in the cerebellum where PNs, one of
the more susceptible neurons to NPC1 deficiency,
undergo a highly organized patterned loss [15,16]. The
sequence of PN loss across cerebellar lobules
(Figure 5A) provides a reliable phenotype for judging the
extent of neuron rescue after a manipulation. As a foun-
dation for the present analysis, we have previously
shown that PN-specific production of NPC1 prevents
patterned neuron loss in otherwise Npc1-/- mice [17].
Here, we assessed whether deletion of C1qa or C3 genes
[3] could modify PN loss. We found that patterned PN
loss was not notably altered in the cerebellum. Purkinje
neurons continued to degenerate throughout cerebellar
lobular zones (Figure 5A, D). Microglial activity and
weight analysis [17] were further used to demonstrate
the absence of significant changes in overall disease pro-
gression (Figure 5B, C-E). We conclude that, in this
mouse model of NPC disease, complement is not
required to mediate neurodegeneration and subsequent
neuroinflammation.
Loss of other immune-related components, or an
apoptosis facilitator, does not alter patterned neuron loss
in NPC mice
Our prior experiments have demonstrated that
neuron death and survival in NPC disease is driven
by more dominant cell-autonomous mechanisms
[2,9,17], and we suggested that immune factors might
have minimal involvement. The continued patterned
neuron loss in NPC disease, even with loss of com-
plement, supports these conclusions. However, many
other immune and inflammatory factors may be
more heavily involved in mediating neurodegenera-
tion. Using existing mutant mice, we have sampled a
few other genes that are substantially over-expressed
in NPC disease based upon reported datasets
[1,2,6,7]. Loss of function of TLR7, an endosomal
Toll-like receptor involved in innate immunity [18],
UNC93b1, an associated mediator of TLR activity
[19], MMP12, an extracellular matrix macrophage
metalloprotease [20], and the pro-apoptotic BH3-only
Bcl-2 family member BCL2L11, also known as BIM,
[21,22] individually did not alter the patterned PN
loss in Npc1-/- mice (Table 1). These results demon-
strate that, despite the evident presence of immune
response and inflammatory mediators, neurons will
die in their typical NPC manner with or without
these factors.
General conclusions
In this study, we show that C1q and other immune fac-
tors do not facilitate the elimination of dying neurons in
the disease. This study agrees with a commonly
employed mouse model of Parkinson disease where
microglial C1q is reported to not affect nigrostriatal
Figure 4 C1q localizes to the perineuronal ECM in the CA2
hippocampus and cerebellar DCN. (A) In Npc1-/- mice, C1q (red)
partially localizes with CSPG (green) of CA2 neurons. Matched image
from a C1qa-/-; Npc1-/- mouse is shown as a control for the C1q
antibody used. Sr denotes the stratum radiatum side of the CA2
field. CA2 neuron bodies (blue) are marked with Nissl stain. Scale
bars are 50μm. (B) A single cerebellar DCN neuron is shown. Scale
bar is 10μm.
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dopaminergic injury [23]. The cell-autonomous and gen-
etically controlled neuron survival in the NPC mouse
model [2,17] provides a tool and opportunity for
uncovering alternate non-apoptotic mechanisms of
neuron death and clearance that may also occur in many
other neurodegenerative disorders.
Figure 5 Complement deficiency does not affect patterned Purkinje neuron death and disease progression. (A) Cerebellar PNs
(anti-D28K, red) in the anterior zone (AZ) die before PNs in the central and posterior zone (CZ and PZ), and PNs in the nodular zone (NZ) survive
regardless of age. This patterned PN loss was not altered by C1q deficiency. (B) C1q deficiency also did not change the level of activity of
microglia cells, marked by anti-CD68 and quantified by percent area occupied in the tissue, throughout the brain. The cerebellar cortex of lobule
III was used to determine the level of microglia activity at P60. (D) Patterned PN (anti-D28K, blue) loss and the inverse pattern of microglial
(anti-CD68, yellow) activity was also detected in C3-/-; Npc1-/- mice. (C, E) Two-way ANOVA analysis on the weight profiles of Npc1-/- mice showed
that neither C1qa (red lines, P = 0.70) nor C3 (blue lines, P = 0.41) deficiency significantly affected disease progression. Non-C1qa or C3 deficient
Npc1-/- sibling mice were used for comparison (dashed lines).
Table 1 Deficiency in other immune response-relevant pathways does not alter neurodegeneration in NPC disease
Npc1-/- & ____ Function/Pathway Micea (n) Change in PN loss Change in microglia Change in %CD68b Ref.
C1qa -/- Complement 11 No No P = 0.49 Figure 5B
C3 -/- Complement 7 No No P = 0.88
Mmp12 -/- ECM degradation 4 No No P = 0.95
Bcl2l11(Bim) -/- Apoptosis 4 No No P = 0.17
Tlr7 -/- Toll-like receptor 3 No No n/a
Unc93b1 3d/3d Toll-like receptor 3 No No n/a
Pcp2-tTA; TetO-Npc1YFP Purkinje neuron (PN) rescue 32 Yes Yes P = 0.0057 [2,17]
aNumber of mice used to observe PN loss and microglial activity for ages >P60, see Figure 5A and 5D.
bTwo-way ANOVA: Does the gene affect %CD68 in the cerebellum or thalamus of Npc1-/- mice compared to Npc1-/- controls? P value <0.05 is considered significant; n =
4 for all mice at age P60. n/a means a statistical analysis was not performed for this group. Hippocampus and midbrain values, which showed no difference across
samples, were used to normalize %CD68 in thalamus and cerebellum, respectively. Note: PN rescue corrects cerebellar but not thalamic pathology [17], P = 0.0005.
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Methods
Mice were managed in accordance with Stanford Uni-
versity’s Administrative Panel on Laboratory Animal
Care. Npc1+/- mice were derived as previously reported
[17] and crossed with C1qa [24] or C3 [25] knockout
mice obtained at Stanford University [3]. Tlr7 [18],
Mmp12 [20], and Bcl2l11(Bim) [21] knockout mice
were obtained from the Jackson Laboratory. Unc93b13d
[19] mutant mice were obtained from the Mutant
Mouse Regional Resource Centers. Genotyping was
performed as detailed in the references listed above.
To minimize background discrepancies, sibling off-
spring were used for comparisons. For example, mixed
FVB/B6 C1qa+/-; Npc1+/- mice were mated to produce
offspring with genotypes Npc1-/-; C1qa+/+ and Npc1-/-;
C1qa-/-. Isolated brains were fixed whole overnight at
4°C in 4% paraformaldehyde in phosphate buffer saline
(PBS).
Immunofluorescent and imaging procedures were
performed as previously described [17]. Primary anti-
body sources are as follows: rat anti-C1q (Abcam), rat
anti-CD68 (AbdSerotec), rabbit and mouse anti-
Calbindin-D28K (Sigma), and mouse anti-CSPG (Milli-
pore). Stainings include Hoechst (Invitrogen) and Neu-
roTrace 435/455 fluorescent Nissl stain (Invitrogen).
ImageJ and GraphPad Prism software were used for
measurements and statistics. Unless stated otherwise,
means and standard deviations are reported.
DIG-labeled antisense probes for in situ detection of
C1qa were designed as previously described [3]. A total
of 200 ng/mL of purified DIG-labeled RNA probe was
hybridized to 50 μm thick vibratome tissue sections
that were processed in RNAse-free 5x SSC buffer.
Hybridization was performed at 60°C for 16 h in
hybridization solution: 50% formamide, 5x SSC, 0.1%
Tween-20, 500 ug/mL tRNA, 500ug/mL salmon sperm
DNA, 50 ug/mL Heparin salt, and 0.5% SDS. Washes
were done at 60°C for 15 min using hybridization buf-
fer followed by 5x SCC and 0.2x SSC buffers with
0.1% Tween-20 (Sigma). Afterwards, PBS with 2% BSA
and 0.2% Triton X-100 (Sigma) was used for incubat-
ing anti-Digoxigenin-AP, Fab fragments (Roche) over-
night at 4°C. The NBT/BCIP or HNPP Fast Red
reaction was then performed as commercially directed
(Roche). To mark CD68-positive cells microglia with
DAB (Sigma), 50 μm vibratome sections were first
treated with 0.6% hydrogen peroxide in methanol for
30 min followed by incubation of anti-CD68 antibody
in PBS with 2% BSA and 0.2% Triton X-100. Diethyl-
pyrocarbonate (DEPC; Sigma) was present in 0.01%
vol/vol concentration throughout the CD68 immuno-
histochemical procedure. Unlike anti-CD68, anti-D28K
can be used after in situ hybridization for immuno-
fluorescent detection of PNs.
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